Arjun Agarwal sold $806k of ORKA
Senior Vice President, Finance at Oruka Therapeutics, Inc.. 9,999 shares at an average of $80.60, traded Oct 12, 2026, filed Oct 13, 2026.
Score components
This filing reached EDGAR on Oct 13, 2026, so its score and components open to free visitors on Oct 20, 2026. The trade itself, the rows in the filing and the price context are public now.
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000907654-26-000106, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | MOption exercise Common Stock10b5-1 | +8,541 | $12.50 | $107k | 22,760 | 9 h ago |
| Oct 12, 2026 | MOption exercise Common Stock10b5-1 | +1,458 | $34.39 | $50k | 24,218 | 9 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -5,741 | $80.03 | $459k | 18,477 | 9 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -2,100 | $80.76 | $170k | 16,377 | 9 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -1,958 | $81.86 | $160k | 14,419 | 9 h ago |
| Oct 12, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $82.84 | $17k | 14,219 | 9 h ago |
| Oct 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -8,541 | $0.00 | $0 | 76,376 | 9 h ago |
| Oct 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,458 | $0.00 | $0 | 56,875 | 9 h ago |
Related signals
Other insiders at Oruka Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $2.1M 25,000 shares | -3% | |
| 17Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $51k 533 shares | -4% | |
| 29Weak | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $936k 10,000 shares | -25% | |
| 29Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $926k 10,019 shares | -40% | |
| 21Weak | Oruka Therapeutics, Inc. | Joana Goncalves Chief Medical Officer | $734k 7,947 shares | -20% | |
| 53Moderate | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $235k 2,452 shares | -0% | |
| 44Moderate | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $87k 906 shares | -0% | |
| 40Moderate | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $99k 1,039 shares | -3% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $6.9M 75,000 shares | -7% | |
| 17Weak | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $459k 5,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.